Dog udp-glucuronosyltransferase enzymes of subfamily 1a: Cloning, expression, and activity

Drug Metabolism and Disposition

Volumn 43, Issue 1, 2015, Pages 107-118

  Troberg, Johanna ^a   Järvinen, Erkka ^a   Muniz, Maria ^a   Sneitz, Nina ^a   Mosorin, Johanna ^a   Hagström, Marja ^a   Finel, Moshe ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ESTRADIOL; COMPLEMENTARY DNA; DEXMEDETOMIDINE; DICLOFENAC; DOG UDP GLUCURONOSYLTRANSFERASE OF SUBFAMILY 1A; ENTACAPONE; ESTRADIOL; ETHINYLESTRADIOL; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; INDOMETACIN; PROPRANOLOL; PROTEIN DUGT1A10; PROTEIN DUGT1A11; PROTEIN DUGT1A2; PROTEIN DUGT1A4; PROTEIN DUGT1A8; UNCLASSIFIED DRUG; GLUCURONIDE;

ANIMAL CELL; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG CONJUGATION; DRUG GLUCURONIDATION; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; MICROSOME; MOLECULAR CLONING; NONHUMAN; PROTEIN EXPRESSION; SPECIES DIFFERENCE; ANIMAL; DOG; GENETICS; INTESTINE; LIVER; METABOLISM; PHYSIOLOGY; PROCEDURES;

ANIMALIA; CANIS FAMILIARIS; HEXAPODA;

ANIMALS; CATALYSIS; CLONING, MOLECULAR; DICLOFENAC; DNA, COMPLEMENTARY; DOGS; ESTRADIOL; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INTESTINES; LIVER; MICROSOMES; PROPRANOLOL; SUBSTRATE SPECIFICITY;

EID: 84919653551     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.059303     Document Type: Article

References (37)

1. Argikar UA (2012) Unusual glucuronides. Drug Metab Dispos 40:1239-1251.
2. Bosma PJ, Chowdhury NR, Goldhoorn BG, Hofker MH, Oude Elferink RPJ, Jansen PLM, and Chowdhury JR (1992) Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar syndrome, type I. Hepatology 15:941-947.
3. Court MH (2005) Isoform-selective probe substrates for in vitro studies of human UDPglucuronosyltransferases. Methods Enzymol 400 : 104-116.
4. Dereeper A, Guignon V, Blanc G, Audic S, Buffet S, Chevenet F, Dufayard JF, Guindon S, Lefort V, and Lescot M, et al. (2008) Phylogeny.fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res 36(Web Server Issue):W465-W469.
5. Furukawa T, Naritomi Y, Tetsuka K, Nakamori F, Moriguchi H, Yamano K, Terashita S, Tabata K, and Teramura T (2014) Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys. Xenobiotica 44:205-216.
6. Heikkinen AT, Friedlein A, Matondo M, Hatley OJ, Petsalo A, Juvonen R, Galetin A, Rostami-Hodjegan A, Aebersold R, and Lamerz J, et al. (2014) Quantitative ADME proteomics-CYP and UGT enzymes in the beagle dog liver and intestine. Pharm Res DOI: 10.1007/s11095-014-1446-8 [published ahead of print].
7. Höglund C, Sneitz N, Radominska-Pandya A, Laakonen L, and Finel M (2011) Phenylalanine 93 of the human UGT1A10 plays a major role in the interactions of the enzyme with estrogens. Steroids 76:1465-1473.
8. Itäaho K, Laakkonen L, and Finel M (2010) How many and which amino acids are responsible for the large activity differences between the highly homologous UDP-glucuronosyltransferases (UGT) 1A9 and UGT1A10? Drug Metab Dispos 38:687-696.
9. Itäaho K, Mackenzie PI, Ikushiro S, Miners JO, and Finel M (2008) The configuration of the 17-hydroxy group variably influences the glucuronidation of b-estradiol and epiestradiol by human UDP-glucuronosyltransferases. Drug Metab Dispos 36:2307-2315.
10. Kaivosaari S, Finel M, and Koskinen M (2011) N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. Xenobiotica 41:652-669.
11. Kaivosaari S, Toivonen P, Aitio O, Sipilä J, Koskinen M, Salonen JS, and Finel M (2008) Regioand stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes. Drug Metab Dispos 36:1529-1537.
12. Kerdpin O, Mackenzie PI, Bowalgaha K, Finel M, and Miners JO (2009) Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDPglucuronosyltransferase1A1, 1A6, 1A9, 2B7, and 2B10. Drug Metab Dispos 37:1948-1955.
13. King CD, Rios GR, Green MD, and Tephly TR (2000) UDP-glucuronosyltransferases. Curr Drug Metab 1:143-161.
14. Kirkness EF, Bafna V, Halpern AL, Levy S, Remington K, Rusch DB, Delcher AL, Pop M, Wang W, and Fraser CM, et al. (2003) The dog genome: survey sequencing and comparative analysis. Science 301:1898-1903.
15. Kurkela M, García-Horsman JA, Luukkanen L, Mörsky S, Taskinen J, Baumann M, Kostiainen R, Hirvonen J, and Finel M (2003) Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. J Biol Chem 278:3536-3544.
16. Kuuranne T, Kurkela M, Thevis M, Schänzer W, Finel M, and Kostiainen R (2003) Glucuronidation of anabolic androgenic steroids by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 31:1117-1124.
17. Kuusela E, Raekallio M, Anttila M, Falck I, Mölsä S, and Vainio O (2000) Clinical effects and pharmacokinetics of medetomidine and its enantiomers in dogs. J Vet Pharmacol Ther 23: 15-20.
18. Lautala P, Ethell BT, Taskinen J, and Burchell B (2000) The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 28:1385-1389.
19. Li C and Wu Q (2007) Adaptive evolution of multiple-variable exons and structural diversity of drug-metabolizing enzymes. BMC Evol Biol 7:69.
20. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ, 3rd, and Zody MC, et al. (2005) Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438:803-819.
21. Luukkanen L, Taskinen J, Kurkela M, Kostiainen R, Hirvonen J, and Finel M (2005) Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 33:1017-1026.
22. Luukkanen L, Kilpeläinen I, Kangas H, Ottoila P, Elovaara E, and Taskinen J (1999) Enzymeassisted synthesis and structural characterization of nitrocatechol glucuronides. Bioconjug Chem 10:150-154.
23. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, and Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685.
24. Murai T, Iwabuchi H, and Ikeda T (2005) Repeated glucuronidation at one hydroxyl group leads to structurally novel diglucuronides of steroid sex hormones. Drug Metab Pharmacokinet 20:282-293.
25. Rowland A, Miners JO, and Mackenzie PI (2013) The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 45:1121-1132.
26. Soars MG, Riley RJ, Findlay KAB, Coffey MJ, and Burchell B (2001a) Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. Drug Metab Dispos 29:121-126.
27. Soars MG, Smith DJ, Riley RJ, and Burchell B (2001b) Cloning and characterization of a canine UDP-glucuronosyltransferase. Arch Biochem Biophys 391:218-224.
28. Soars MG, Fettes M, O'Sullivan AC, Riley RJ, Ethell BT, and Burchell B (2003) Cloning and characterisation of the first drug-metabolising canine UDP-glucuronosyltransferase of the 2B subfamily. Biochem Pharmacol 65:1251-1259.
29. Sten T, Bichlmaier I, Kuuranne T, Leinonen A, Yli-Kauhaluoma J, and Finel M (2009) UDPglucuronosyltransferases (UGTs) 2B7 and UGT2B17 display converse specificity in testosterone and epitestosterone glucuronidation, whereas UGT2A1 conjugates both androgens similarly. Drug Metab Dispos 37:417-423.
30. Sten T, Qvisen S, Uutela P, Luukkanen L, Kostiainen R, and Finel M (2006) Prominent but reverse stereoselectivity in propranolol glucuronidation by human UDP-glucuronosyltransferases 1A9 and1A10. Drug Metab Dispos 34:1488-1494.
31. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
32. Walsky RL, Bauman JN, Bourcier K, Giddens G, Lapham K, Negahban A, Ryder TF, Obach RS, Hyland R, and Goosen TC (2012) Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metab Dispos 40:1051-1065.
33. Zhang H, Patana AS, Mackenzie PI, Ikushiro S, Goldman A, and Finel M (2012a) Human UDPglucuronosyltransferase expression in insect cells: ratio of active to inactive recombinant proteins and the effects of a C-terminal his-tag on glucuronidation kinetics. Drug Metab Dispos 40:1935-1944.
34. Zhang H, Soikkeli A, Tolonen A, Rousu T, Hirvonen J, and Finel M (2012b) Highly variable pH effects on the interaction of diclofenac and indomethacin with human UDP-glucuronosyltransferases. Toxicol In Vitro 26:1286-1293.
35. Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z, Sinz M, and Rodrigues AD (2007) Pharmacokinetic drug interactions involving 17a-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 46:133-157.
36. Zhou J, Tracy TS, and Remmel RP (2010) Bilirubin glucuronidation revisited: proper assay conditions to estimate enzyme kinetics with recombinant UGT1A1. Drug Metab Dispos 38:1907-1911.
37. Zhu L, Ge G, Zhang H, Liu H, He G, Liang S, Zhang Y, Fang Z, Dong P, and Finel M, et al. (2012) Characterization of hepatic and intestinal glucuronidation of magnolol: application of the relative activity factor approach to decipher the contributions of multiple UDPglucuronosyltransferase isoforms. Drug Metab Dispos 40:529-538.